Terms: = Ovarian cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207
2168 results:
1. Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.
Liang H; Geng S; Wang Y; Fang Q; Xin Y; Li Y
J Cell Mol Med; 2024 May; 28(9):e18315. PubMed ID: 38680032
[TBL] [Abstract] [Full Text] [Related]
2. Endometriosis-Associated ovarian cancer: From Molecular Pathologies to Clinical Relevance.
Steinbuch SC; Lüß AM; Eltrop S; Götte M; Kiesel L
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673891
[TBL] [Abstract] [Full Text] [Related]
3. MATN2 overexpression suppresses tumor growth in ovarian cancer via PTEN/PI3K/akt pathway.
Liu J; Zhang J; Zhang Y; Yang B; Liu H; Chen Y
Funct Integr Genomics; 2024 Apr; 24(2):71. PubMed ID: 38568332
[TBL] [Abstract] [Full Text] [Related]
4. A miRNA-7704/IL2RB/akt feedback loop regulates tumorigenesis and chemoresistance in ovarian cancer.
Meng X; Liang X; Yang S; Wu D; Wang X
Exp Cell Res; 2024 Apr; 437(2):114012. PubMed ID: 38565343
[TBL] [Abstract] [Full Text] [Related]
5. Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.
Xia Y; Wang S; Sun Y; Wang W; Chang S; Zhang Z; Zhao C
Cell Commun Signal; 2024 Mar; 22(1):194. PubMed ID: 38539211
[TBL] [Abstract] [Full Text] [Related]
6. Diosgenin inhibits proliferation and migration of ovarian cancer cells and induce apoptosis via upregulation of PTEN.
Fang F; Zhang X; Fang Y
Chem Biol Drug Des; 2024 Mar; 103(3):e14459. PubMed ID: 38538058
[TBL] [Abstract] [Full Text] [Related]
7. The roles of autophagy, ferroptosis and pyroptosis in the anti-ovarian cancer mechanism of harmine and their crosstalk.
Zhu J; Zhu H; Zhu Q; Xu SL; Xiao L; Zhang MY; Gao J
Sci Rep; 2024 Mar; 14(1):6504. PubMed ID: 38499622
[TBL] [Abstract] [Full Text] [Related]
8. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
[TBL] [Abstract] [Full Text] [Related]
9. akting on R Loops Makes for an ATractive Target in ovarian cancer Therapy.
Ramanarayanan V; Oberdoerffer P
Cancer Res; 2024 Mar; 84(6):793-795. PubMed ID: 38486481
[TBL] [Abstract] [Full Text] [Related]
10. TOP2A modulates signaling via the akt/mTOR pathway to promote ovarian cancer cell proliferation.
Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
[TBL] [Abstract] [Full Text] [Related]
11. Periostin's role in uterine leiomyoma development: a mini-review on the potential periostin poses as a pharmacological intervention for uterine leiomyoma.
Kiesler ZG; Hunter MI; Balboula AZ; Patterson AL
Arch Gynecol Obstet; 2024 May; 309(5):1825-1831. PubMed ID: 38441600
[TBL] [Abstract] [Full Text] [Related]
12. TMED3 stabilizes SMAD2 by counteracting NEDD4-mediated ubiquitination to promote ovarian cancer.
Chen X; Zhang W; Han X; Li X; Xia L; Wu Y; Zhou Y
Mol Carcinog; 2024 May; 63(5):803-816. PubMed ID: 38411267
[TBL] [Abstract] [Full Text] [Related]
13. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-akt pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
14. The miR-1290/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion.
Jiang B; Xiao S; Zhang S; Xiao F
J Ovarian Res; 2024 Feb; 17(1):52. PubMed ID: 38402185
[TBL] [Abstract] [Full Text] [Related]
15. Novel prognostic marker TGFBI affects the migration and invasion function of ovarian cancer cells and activates the integrin αvβ3-PI3K-akt signaling pathway.
Wang H; Xu YH; Guo Y
J Ovarian Res; 2024 Feb; 17(1):50. PubMed ID: 38395907
[TBL] [Abstract] [Full Text] [Related]
16. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
17. VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/ERK signaling pathway.
Wang Q; Tang Y; Dai A; Li T; Pei Y; Zhang Z; Hu X; Chen T; Chen Q
Appl Microbiol Biotechnol; 2024 Feb; 108(1):218. PubMed ID: 38372808
[TBL] [Abstract] [Full Text] [Related]
18. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract] [Full Text] [Related]
19. β-Sitosterol targets ASS1 for Nrf2 ubiquitin-dependent degradation, inducing ROS-mediated apoptosis via the PTEN/PI3K/akt signaling pathway in ovarian cancer.
Wang H; Liu J; Zhang Z; Peng J; Wang Z; Yang L; Wang X; Hu S; Hong L
Free Radic Biol Med; 2024 Mar; 214():137-157. PubMed ID: 38364944
[TBL] [Abstract] [Full Text] [Related]
20. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
Arai H; Yang Y; Baca Y; Millstein J; Denda T; Ou FS; Innocenti F; Takeda H; Kubota Y; Doi A; Horie Y; Umemoto K; Izawa N; Wang J; Battaglin F; Jayachandran P; Algaze S; Soni S; Zhang W; Goldberg RM; Hall MJ; Scott AJ; Hwang JJ; Lou E; Weinberg BA; Marshall J; Goel S; Xiu J; Michael Korn W; Venook AP; Sunakawa Y; Lenz HJ
Eur J Cancer; 2024 Apr; 201():113914. PubMed ID: 38359495
[TBL] [Abstract] [Full Text] [Related]
[Next]